RxDoctor Payments Data

Bruce Roe, PA

Physician Assistant · Rocklin, CANPI 1356433262

Payments from drug & device makers

$10,441in general payments, 2019–2025

Across 565 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$972
  • Novo Nordisk$698
  • Boehringer Ingelheim$669
  • Lilly USA, LLC$520
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$10,441100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,441 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$26,670
Medicare patients
153
Services billed
3,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide23$22,275
RybelsusSemaglutide15$19,179
JardianceEmpagliflozin17$15,470
EliquisApixaban13$14,831
OzempicSemaglutide15$13,881
VascepaIcosapent Ethyl17$9,291
Icosapent Ethyl11$2,242
SynthroidLevothyroxine Sodium20$1,431
Atorvastatin Calcium123$1,019
Humulin NInsulin Nph Human Isophane11$929
Rosuvastatin Calcium92$860
Tamsulosin Hcl52$772
Fenofibrate14$699
Levothyroxine Sodium82$689
Valsartan13$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$698$33,06030 claims
Lilly USA, LLCMounjaro, Humulin N$520$23,20534 claims
Boehringer IngelheimJardiance$669$15,47017 claims
PfizerEliquis$498$14,83113 claims
AbbVieSynthroid$2,181$1,43120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Rocklin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →